Vandortuzumab vedotin (DSTP3086S / RG7450 / MSTP2109A) Clinical Trials

TrialTitleStudy Record DetailPhaseSponsor/Collaborator
A Study of the Safety and Pharmacokinetics of Escalating Doses of DSTP3086S in Patients With Metastatic Castration-Resistant Prostate CancerNCT01283373Phase IGenentech, Inc.
Study of 89Zr-DFO-MSTP2109A in Patients With Prostate CancerNCT01774071Phase I /Phase IIMemorial Sloan Kettering Cancer Center/Genentech Inc

The Anti-STEAP1 antibody-drug conjugate DSTP3086S / RG7450 is also known as MSTP2109A.

Last Editorial Review: August 12, 2015